XXXX : Analysis of treatment outcome from a tertiary care center.

@entity1 @entity632 @entity900 @entity1349 @entity4177
AIM: This study was designed to retrospectively review our experience with the multimodality management of @entity4177 ( @entity4177 ). MATERIALS AND METHODS: Thirteen @entity1 were treated for @entity4177 between 2000 and 2007. The clinical presentations, chemotherapy tolerance and response, surgical procedure undertaken, and complications were analysed. RESULTS: Median age of the population was 12 months (3-60 months), with a male-to-female ratio of 3.3:1. Nine @entity1 were treated with neoadjuvant chemotherapy incorporating @entity900 and @entity632 . Primary surgery was done in four @entity1 . Extent of hepatic resection in the operated @entity1 varied. Mixed type was the predominant histopathological diagnosis. Adjuvant chemotherapy was well tolerated with no morbidity or mortality. Five-year event-free survival (EFS) and @entity1349 ( @entity1349 ) of all the 13 @entity1 is 76.9%. All the nine @entity1 who could complete multimodality treatment are alive with no evidence of disease or complications with median follow-up of 63 months (46-122 months). CONCLUSIONS: Treatment of @entity4177 with multidisciplinary approach was well tolerated. @entity1349 and EFS of @entity1 were comparable with published studies.
